1. Key Questions for nAMD Treatment Success

3. Program Overview

4. Question: VA at Presentation

5. Improved Visual Outcomes in RCTs

6. VA Gains Greater in Patients With nAMD Who Have Lower Baseline VA

7. Vision is Better Preserved After 1 Year in Patients With Higher Baseline VA

8. Question: The Role of PCV Subtype

9. Effect of PCV Status on VA Gain in Treatment-Naive Patients With nAMD

10. Other Data on the Effect of PCV and PED Subtype on VA

11. Question: The Importance of the Loading Dose

12. Better Gains in VA at 12 Months With Loading Dose of Ranibizumab

13. Patients Who Received a Loading Dose Had a Greater Improvement in VA

14. Question: Intensive Therapy

15. The Effect of Intensive Anti-VEGF Therapy

16. Question: PRN or T&E

17. VA Gains at 12 Months With Different Treatment Regimens

18. Similar Gains in VA and Fewer Injections With T&E vs Monthly Dosing

19. T&E Has Greater Benefits Than PRN

20. Question: Injection Frequency

21. Pivotal Trials: Significant VA Gains With Monthly Anti-VEGF Therapy

22. Monthly Anti-VEGF Therapy vs PRN and T&E

23. PRN: Greater VA Gains With a Higher Injection Frequency

24. Barriers to Adequate Treatment

25. Question: Choice of Anti-VEGF Treatment

26. Ranibizumab vs Aflibercept

27. Question: Safety of Anti-VEGF Treatment

28. Safety of Ranibizumab

29. Summary

30. Abbreviations

31. Abbreviations (cont)